ProCE Banner Activity

CE / CME

My Take on the Most Clinically Relevant New Data in Atopic Dermatitis

Conference Coverage
Clinical Thought
Following the virtual 2020 American Academy of Dermatology and Revolutionizing Atopic Dermatitis conferences, I describe several of the most clinically relevant data on approved and investigational treatments that have the potential to improve outcomes for our patients.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: August 10, 2020

Expiration: August 09, 2021

No longer available for credit.

Share

Faculty

Andrew F. Alexis

Andrew F. Alexis, MD, MPH

Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Director, Skin of Color Center
Mount Sinai West and Mount Sinai Morningside
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.

Target Audience

The primary target audience for the activities includes dermatologists, immunologists, nurses, and other healthcare providers who treat patients with moderate to severe AD.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Critically evaluate study results from recent trials of AD regarding treatment efficacy and safety
  • Describe how new trial data will affect/change the management of patients with AD

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Andrew F. Alexis, MD, MPH

Professor
Department of Dermatology
Icahn School of Medicine at Mount Sinai
Director, Skin of Color Center
Mount Sinai West and Mount Sinai Morningside
New York, New York

Andrew Alexis, MD, MPH, has disclosed that he has received contracted research support from Almirall, Bristol-Myers-Squibb, Cara, Celgene, Galderma, Leo, Menlo, Novartis, and Valeant (Bausch Health); and has served as a consultant for Beiersdorf, Bristol-Myers-Squibb, Cassiopea, Celgene, Dermavant, Foamix, Galderma, Leo, L’Oreal, Menlo, Novartis, Pfizer, Sanofi-Regeneron, Scientis, UCB, Unilever, and Valeant (Bausch Health).

Staff Disclosure

Staff

Kiran Mir-Hudgeons, PhD

Clinical Editor

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 10, 2020, through August 09, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this initiative is to provide dermatologists and allergists with data on current and emerging therapies for moderate to severe AD presented at the virtual RAD 2020 and AAD 2020 conferences.